Core Viewpoint - China Hongqiao announced that its controlling shareholder, Hongqiao Holdings, will place shares to independent subscribers while also subscribing for newly issued shares of the company. The placement and subscription price is set at HKD 29.20 per share, representing a discount of approximately 9.60% from the previous trading day's closing price. The expected net proceeds from this subscription will be around HKD 11.49 billion, which the company plans to use for domestic and international project development, debt repayment to optimize capital structure, and to supplement working capital and general corporate purposes [1]. Group 1 - The controlling shareholder, Hongqiao Holdings, will conduct a share placement to independent subscribers [1] - The subscription price is set at HKD 29.20 per share, reflecting a discount of about 9.60% from the last closing price [1] - The expected net proceeds from the subscription are approximately HKD 11.49 billion [1] Group 2 - The funds raised will be allocated for domestic and international project development [1] - The company plans to use part of the proceeds for debt repayment to optimize its capital structure [1] - Additional uses of the funds include supplementing working capital and general corporate purposes [1]

Core Viewpoint - Horizon Robotics-W (09660) has announced a placement and subscription agreement aimed at optimizing its capital structure and supporting sustainable development, with a net estimated proceeds of approximately HKD 6.339 billion [1] Group 1: Placement and Subscription Agreement - The company and existing shareholders have entered into an agreement where existing shareholders agree to sell shares at a placement price of HKD 9.99 per share [1] - The placement price represents a discount of approximately 5.75% compared to the last closing price of HKD 10.60 per share on the Stock Exchange [1] - Existing shareholders conditionally agree to subscribe for shares at the same placement price of HKD 9.99 per share [1] Group 2: Use of Proceeds - The estimated net proceeds of approximately HKD 6.339 billion will be used to optimize the company's capital structure [1] - The funds are intended to support the company's health and sustainable development initiatives [1]

Group 1 - The company Yunfeng Financial (00376) has completed a placement of shares on September 18, 2025, under the terms of the placement and subscription agreement [1] - A total of 191.3 million existing shares were successfully placed at a price of HKD 6.10 per share to no fewer than six subscribers, all of whom are independent third parties [1] - Following the completion of the subscription, the total amount raised from the subscription was approximately HKD 1.17 billion, with a net amount of approximately HKD 1.15 billion [1] Group 2 - After the completion of the placement and subscription, no subscriber has become a major shareholder of the company [1] - All conditions for the completion of the subscription have been met, leading to the issuance of 191.3 million subscription shares at the same price of HKD 6.10 per share on September 23, 2025 [1]

Core Viewpoint - 康诺亚-B (02162.HK) has entered into a placement and subscription agreement to sell and issue shares, aiming to raise approximately HKD 864 million for various purposes [1][2]. Group 1: Share Placement and Subscription - The total number of shares to be placed is 21.6 million, representing about 7.72% of the company's issued shares as of the announcement date [2]. - The subscription involves 19 million new shares, accounting for approximately 6.36% of the enlarged share capital post-placement and subscription [2]. - Following the completion of the placement and subscription, the selling shareholder's stake will decrease from about 27.79% to approximately 25.16% of the enlarged issued share capital [2]. Group 2: Pricing and Financial Details - The placement price is set at HKD 45.48 per share, which is a discount of approximately 6.52% compared to the closing price of HKD 48.65 on June 10 [2]. - The total expected proceeds from the subscription are approximately HKD 864 million, with net proceeds estimated at around HKD 854 million [2]. Group 3: Use of Proceeds - The net proceeds are planned to be allocated as follows: approximately 35% for R&D expenses related to CM512, CM518D1, and other pipelines; about 30% for the commercialization of the drug Siplizumab; around 25% for capital expenditures on manufacturing and R&D facilities; and 10% for general corporate and operational purposes [2].

Core Viewpoint - 康诺亚-B (02162) has entered into a placement and subscription agreement to sell and issue shares, aiming to raise approximately HKD 854 million for various development and operational purposes [1][2]. Group 1: Share Placement and Subscription - The total number of shares to be placed is 21.6 million, representing approximately 7.72% of the company's issued shares as of the announcement date [2]. - The number of subscription shares is 19 million, accounting for about 6.36% of the expanded share capital post-placement and subscription [2]. - The placement price is set at HKD 45.48 per share, which is a discount of approximately 6.52% compared to the closing price of HKD 48.65 on June 10, 2025 [2]. Group 2: Use of Proceeds - The net proceeds from the subscription, estimated to be around HKD 854 million after deducting commissions and estimated expenses, will be allocated for: - Research and development expenses for CM512, CM518D1, and other pipeline projects [2]. - Commercialization of the drug Siplizumab [2]. - Capital expenditures for manufacturing and research facilities [2]. - General corporate and operational funding [2].